‘Knock out the middlemen’: A campaign promise Donald Trump should keep
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Forbes1y
Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita
Express Scripts even blocked both the branded reference product – Lantus - and the lower-priced ... as a percentage of the list (not net) price – will then pay more out-of-pocket.
pharmaphorum3d
Civica plans shake-up of insulin sector with low-cost biosimilars
The average wholesale prices of the originator insulin are around ... to secure FDA approval for a biosimilar product version of Lantus – Semglee – that is completely interchangeable with ...